[
  {
    "ts": null,
    "headline": "Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment",
    "summary": "Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus Holdings announced its participation in the newly launched FIBRE Consortium, which is a collaborative initiative with Pfizer Inc. (NYSE:PFE) and Lumina Pharmaceuticals. The consortium’s primary goal is to revolutionize the treatment of fibrotic diseases by using […]",
    "url": "https://finnhub.io/api/news?id=dd29f58b9f69c0eb4696cef22ff623b3054fec42b2b889853390bff89191c344",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751098579,
      "headline": "Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment",
      "id": 135606800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus Holdings announced its participation in the newly launched FIBRE Consortium, which is a collaborative initiative with Pfizer Inc. (NYSE:PFE) and Lumina Pharmaceuticals. The consortium’s primary goal is to revolutionize the treatment of fibrotic diseases by using […]",
      "url": "https://finnhub.io/api/news?id=dd29f58b9f69c0eb4696cef22ff623b3054fec42b2b889853390bff89191c344"
    }
  }
]